Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Coronavirus, Strain

Verify with FDA CVM →

13 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
3
Deaths Reported
2310.0%
Death Rate

Active Ingredients

Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Coronavirus, Strain

Administration Routes

Subcutaneous

Species Affected

Dog 13

Most Affected Breeds

Retriever - Labrador 3
Chihuahua 2
Shepherd Dog - Belgian Malinois 1
Terrier - Yorkshire 1
Crossbred Canine/dog 1
Dalmatian 1
Siberian Husky 1
Terrier - Jack Russell 1
Spaniel - Springer English 1
Schnauzer - Miniature 1

Most Reported Reactions

Vomiting 5
Lethargy (see also Central nervous system depression in 'Neurological') 2
Weight loss 2
Not eating 2
Eosinopenia 2
Lack of efficacy (virus) - parvovirus (including feline panleukopenia) 2
Death 2
Medication error NOS 2
Decreased appetite 1
Third eyelid extrusion 1
Anal and rectal disorder NOS 1
Anaemia NOS 1

Outcome Breakdown

Ongoing
7 (46.7%)
Recovered/Normal
3 (20.0%)
Outcome Unknown
2 (13.3%)
Died
2 (13.3%)
Euthanized
1 (6.7%)

Data Summary

Metric Value
Total adverse event reports 13
Reports involving death 3
Case-fatality rate (reported events) 2310.0%
Distinct species in reports 1
Distinct breeds in reports 10
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Coronavirus, Strain Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 13 adverse event reports referencing Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Coronavirus, Strain, including 3 reports in which the animal died — a 2310.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Coronavirus, Strain. Reported administration route is Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Coronavirus, Strain reports are Dog (13 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (3), Chihuahua (2), Shepherd Dog - Belgian Malinois (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Coronavirus, Strain are Vomiting (5), Lethargy (see also Central nervous system depression in 'Neurological') (2), Weight loss (2), Not eating (2). Of the 15 reports with a coded outcome, Ongoing is the leading category at 46.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Coronavirus, Strain.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial